


Express Mail Label No. EV804431422US
Date of Deposit: February 27, 2007

Attorney Docket No.: VPI/02-110 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/609,147
Confirmation No.: 6705
Filing Date: June 27, 2003
Examiner: Paul V. Ward
Group Art Unit: 1624
Applicants: Knegt et al.
For: CASPASE INHIBITORS AND USES THEREOF

Certificate of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as Express Mail Label No. EV804431422US in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 27, 2007.


Melissa R. Ponziano

February 27, 2007
Cambridge, Massachusetts

Mail Stop: RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith is a Request for Continued Examination (RCE) Transmittal, a Supplemental Information Disclosure Statement, a Form 1449/PTO with copies of references B1-B5 and C1-C7 to be filed in the above-identified patent application.

Applicant: Knegt et al.	
Application No.: 10/609,147	

FEE FOR ADDITIONAL CLAIMS

☒ A fee for additional claims is not required.

☐ A fee for additional claims is required.

The additional fee has been calculated as shown below:

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEES
TOTAL CLAIMS	-	* =	X \$ 50	= \$ 0
INDEPENDENT CLAIMS	-	** =	X \$200	= \$ 0
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM		+	\$360	= \$
* If less than 20, insert 20.				TOTAL \$ <u>0</u>
** If less than 3, insert 3.				

☐ A check in the amount of \$__ in payment of the filing fee is transmitted herewith.

☐ Please charge \$__ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

☐ The following extension is applicable to the Response filed herewith; ☐ \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,590.00 extension fee for response within fourth month

Applicant: Knegtel et al.	
Application No.: 10/609,147	

pursuant to 37 C.F.R. § 1.136(a); ☐ \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).

- ☐ A check in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☐ Please charge the extension fee in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☒ Please charge **\$790.00** to Deposit Account No. 50-0725 in payment of the RCE (Request for Continued Examination) and filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Susan C. Kelly, Reg. No. 58,046

Agent for Applicants

Lisa A. Dixon, Reg. No. 40,995

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242


Tel.: (617) 444-7374

Fax.: (617) 444-6483

Customer No. 27916

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/609,147
Confirmation No.: 6705
Filing Date: June 27, 2003
Examiner: Paul V. Ward
Group Art Unit: 1624
Applicants: Knegt et al.
For: CASPASE INHIBITORS AND USES THEREOF



February 27, 2007
Cambridge, Massachusetts

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- ☒ Copies of references Citation Nos. **B1-B5; C1-C7** are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.
- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☒ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart

foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or

☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and


☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and

☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. ____50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,


Susan C. Kelly, Reg. No. 58,046
Agent for Applicants
Lisa A. Dixon, Reg. No. 40,995
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 444-7374
Fax.: (617) 444-6483
Customer No. 27916